Evidence map›Paper›PMID 40877926›Full record

ReviewCell communication and signaling : CCS2025

MSP-RON signaling in liver pathobiology and as an emerging therapeutic target: a review of the current evidence.

Kai Wu, Jia Ji, Jingying Pan, Miaojin Zhu, Jiale Zhang, Ting Sun, Dan Lv, Mudan Wei, Minghai Wang, Hangping Yao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kai WuState Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Jia JiState Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Jingying PanState Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Miaojin ZhuState Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Jiale ZhangState Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Ting SunState Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Dan LvWenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer- related Pathogens and Immunity, Institute of Tropical Medicine, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Mudan WeiZhejiang Key Laboratory of High-level Biosafety and Biomedical Transformation, Hangzhou Medical College, Hangzhou, 311305, China.
Minghai WangState Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China. minghai.wang@ttuhsc.edu.
Hangping YaoState Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China. yaohangping@zju.edu.cn.

Funding

Fundamental Research Funds for the Central Universities 2022ZFJH003National Natural Sciences Foundation of China 82473937Zhejiang Plan for the Special Support for Top-notch Talents in China 2022R52029
6 · The paper itself

Abstract

The liver is a crucial organ in the human body and is responsible for various functions, including digestion, detoxification, metabolism, and immune response. Proper hepatic function is vital for maintaining systemic homeostasis, and dysregulation of liver signaling pathways contributes to various diseases. Recepteur d'Origine Nantais (RON) is a transmembrane receptor tyrosine kinase that is activated by macrophage-stimulating protein (MSP) and coordinates cell fate decisions through the activation of downstream signaling cascades. As the predominant source of MSP in humans, the liver establishes a liver-specific MSP‒RON autocrine‒paracrine signaling axis that contributes to hepatic regeneration, metabolism, and immune functions. Extensive research has demonstrated that MSP-RON signaling is involved in steatotic liver diseases, hepatitis, cirrhosis, cholestatic liver disease, and liver cancer, highlighting the importance of RON in the development of liver diseases. This review demonstrates the role of the MSP-RON pathway both in maintaining liver homeostasis and in driving disease onset and progression while exploring its signaling mechanisms and therapeutic potential for liver disorders.

Indexed as

Hepatocyte Growth FactorLiverLiver DiseasesMolecular Targeted TherapyProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesSignal TransductionAnimalsHumansHepatocyte Growth Factormacrophage stimulating proteinProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesRON proteinLiver homeostasisLiver immunologyLiver metabolismLiver pathobiologyMSP-RON signaling axisTargeted therapies

Identifiers

PMID40877926
PMCPMC12392513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.